Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant 如閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

This Application Form uses the same terms as defined in the prospectus of SinoMab BioScience Limited (the “ Company ”) dated October 31, 2019 (the “ Prospectus ”). 本申請表格使用中國抗體製藥有限公司（「 本公司 」）於二零一九年十月三十一日刊發的招股章程（「 招股章程 」）所界 Staple your 定的詞語。 Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any payment here Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered 請將股款 or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.本申請表格及招股章程概不構成在香港以外司法權區要約出售或游說要約購買香港發售股份。若無根據美國證 緊釘在此 券法登記或豁免登記，香港發售股份不得在美國提呈發售或出售。 This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. 在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法權區內概不得發送或派發或複製（不論方式，也不論全部或部分）本申請表格及招股章程。 Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies and Available for Inspection” in Appendix V to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 38D of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”), Hong Kong Securities Clearing Company Limited (“ HKSCC ”), the Securities and Futures Commission of Hong Kong (the “ SFC ”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents. 招股章程、所有相關申請表格及招股章程附錄五「送呈公司註冊處處長及備查文件」一節所述其他文件已遵照香港法例第 32 章公司（清盤及雜項條文）條例第 38D 條的規定，送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司（「 聯交所 」）、香港中央結算有限公司（「 香港結算 」）、香港證券及期貨事務監察委員會（「 證監會 」）及香港公司註冊處處長對此等文件的內容概不負責。 SinoMab BioScience Limited 中國抗體製藥有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立的有限公司） Stock Code : 3681 股份代號 : 3681 Offer Price : Not more than HK$9.60 per Offer Share and expected to be not less than HK$7.60 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars and subject to refund) 發售價 : 不超過每股發售股份 9.60 港元且預期不少於每股發售股份 7.60 港元，另加 1% 經紀佣金、0.0027% 證監會交易徵費及 0.005% 聯交所交易費（須於申請時以港元繳足，多繳股款可予退還） You should read this Application Form in conjunction with the Prospectus, which contains further information on the application procedures. 招股章程尚有關於申請程序的其他資料，本申請表格應與招股章程一併閱讀。 Application Form 申請表格 To: SinoMab BioScience Limited 致：中國抗體製藥有限公司 Joint Sponsors 聯席保薦人 Joint Global Coordinators 聯席全球協調人 Joint Bookrunners 聯席賬簿管理人 Joint Lead Managers 聯席牽頭經辦人 Hong Kong Underwriters 香港包銷商

Applicants’ declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “Effect of completing and submitting this Application Form” section of this Application Form.

Warning: Only one application may be made for the benefit of any person. Please refer to the last four bullets of the “Effect of completing and submitting this Application Form” section of this Application Form.

申請人聲明

本人 ~~╱~~ 吾等同意本申請表格及招股章程的條款及條件以及申請程序。見本申請表格「填交本申請表格的效用」一節。

警告：任何人士只限作出一次為其利益而進行的認購申請。請 ~~參~~ 閱本申請表格「填交本申請表格的效用」一節最後四點。

Signed by (all) applicant(s) (all joint applicants must sign): For Broker use 此欄供經紀填寫 Lodged by 遞交申請的經紀由（所有）申請人簽署（所有聯名申請人必須簽署）： Broker No. 經紀號碼 Broker’s Chop 經紀印章 Date: 日期 : ╱ ╱ D 日 M 月 Y 年 Number of Hong Kong Offer Shares applied for (not more than 9,106,500 Shares) 申請香港發售股份數目（不超過 9,106,500 股） Cheque/banker’s cashier order number 支票╱銀行本票號碼 Name of bank on which cheque/banker’s cashier order is drawn Total amount 總額 (see “How to make your application” section) 兌現支票╱銀行本票的銀行名稱（見「申請手續」一節） HK$ 港元 Name in English (in BLOCK letters) 英文姓名╱名稱（正楷） Family name or company name 姓氏或公司名稱 Forename(s) 名字 Name in Chinese 中文姓名╱名稱 Family name or company name 姓氏或公司名稱 Forename(s) 名字 Occupation in English 職業（以英文填寫） Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No.[#] (Please delete as appropriate) 香港身份證號碼╱ 護照號碼╱香港商業登記號碼（請刪除不適用者）[#] Names of all other joint applicants in English (if any, in BLOCK letters) Hong Kong Identity Card No./Passport No./Hong Kong Business 所有其他聯名申請人的英文姓名╱名稱（如有，正楷） Registration No. of all other joint applicants[#] (Please delete as appropriate) 所有其他聯名申請人的香港身份證號碼╱護照號 1) 碼╱香港商業登記號碼（請刪除不適用者）[#] 1) 2) 2) 3) 3) Hong Kong address in English and telephone no. (joint applicants should give the address and the telephone number of first-named applicant only, in BLOCK letters) 香港地址（以英文正楷填寫）及電話號碼（聯名申請人只須填寫排名首位申請人的地址及電話號碼） Telephone No. 電話號碼 For Nominees: You will be treated as applying for your own benefit if you do not complete this section. Please provide an THIS BOX MUST BE DULY COMPLETED account number or identification code for each (joint) beneficial 必須填妥此欄 owner. 由代名人遞交：代名人若不填寫本節，是項認購申請將視作為閣下利益提出。請填寫每名（聯名）實益擁有人的 Participant I.D. of the CCASS Investor Participant or designated CCASS Participant 中央結算系統投資者戶口持有人或指定的中 賬戶號碼或識別編碼。 央結算系統參與者的參與者編號

ADDRESS LABEL 地址標貼 (Your name(s) and address in Hong Kong in BLOCK letters 請用英文正楷填寫 姓名╱名稱 及香港地址）

For designated CCASS Participant or Corporate CCASS Investor Participant, please also affix the company chop bearing its company name 指定的中央結算系統參與者或中央結算系統公司投資者戶口持有人，請加蓋顯示公司名稱的公司印鑑

For internal use 此欄供內部使用

(See paragraph 2 in the section “How to make your application”) （請參閱「申請手續」一節第 2 段）

(1) If you are a CCASS Investor Participant, only a Hong Kong Identity Card number (if you are an individual) or a Hong Kong Business Registration number (if you are a body corporate) will be accepted for this application, please see paragraph 2 under the section “How to make your application”. 如閣下為中央結算系統投資者戶口持有人，是項申請僅接納香港身份證號碼（如屬個別人士）或香港商業登記號碼（如屬法人團體）；請參閱「申請手續」一節第 2 段。 (2) If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For an individual, you must provide your Hong Kong Identity Card number or passport number. If you hold a Hong Kong Identity Card, please provide that number. If you do not hold a Hong Kong Identity Card, please provide your passport number. For a body corporate, please provide your Hong Kong Business Registration number. 如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：如屬個別人士，必須填寫閣下的香港身份證號碼或護照號碼（持有香港身份證者請填寫香港身份證號碼，否則請填寫護照號碼）；如屬法人團體，請填寫香港商業登記號碼。 (3) Part of the Hong Kong Identity Card number/passport number of you or, for joint applicants, the first-named applicant may be printed on your refund cheque (if any). Such data will be used for checking the validity of Application Form and such data would also be transferred to a third party for such purpose and refund purpose. Your banker may require verification of your Hong Kong Identity Card number/passport number before you can cash your refund cheque. 日後如需退回申請股款，退款支票上或會印有閣下或（如屬聯名申請人）排名首位申請人的香港身份證號碼╱護照號碼的一部分。有關資料將用於核實申請表格的有效性，亦會轉交第三方作資料核實和退款。銀行兌現退款支票前或會要求查證閣下的香港身份證號碼╱護照號碼。 (4) If an application is made by an unlisted company and: ‧ the principal business of that company is dealing in securities; and ‧ you exercise statutory control over that company, then the application will be treated as being made for your benefit. 倘若申請人是一家非上市公司，而： ‧ 該公司主要從事證券買賣業務；及 ‧ 閣下對該公司可行使法定控制權，是項申請將視作為閣下的利益提出。 (5) All joint applicants must give (if they are individuals) their Hong Kong Identity Card numbers or, where applicable, passport numbers, or (if they are bodies corporate) their Hong Kong Business Registration numbers.

所有聯名申請人必須提供（如屬個別人士）其香港身份證號碼或（如適用）護照號碼，或（如屬法人團體）其香港商業登記號碼。

This page is intentionally left blank 此乃白頁特意留空

How to make your application

Use the table below to calculate how much you must pay. Your application must be for a minimum of 300 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 300 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.	1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 300 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.	1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 300 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.	1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 300 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.
SinoMab BioScience Limited (Stock Code 3681) (HK$9.60 per Hong Kong Offer Share) NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
No. of Hong Kong Offer Shares applied for Amount payable on application HK$	No. of Hong Kong Offer Shares applied for Amount payable on application HK$	No. of Hong Kong Offer Shares applied for Amount payable on application HK$	No. of Hong Kong Offer Shares applied for Amount payable on application HK$
300 600 900 1,200 1,500 1,800 2,100 2,400 2,700 3,000 4,500 2,909.02 5,818.05 8,727.06 11,636.09 14,545.11 17,454.13 20,363.15 23,272.17 26,181.20 29,090.22 43,635.33	6,000 7,500 9,000 10,500 12,000 13,500 15,000 30,000 45,000 60,000 75,000 58,180.44 72,725.54 87,270.65 101,815.76 116,360.87 130,905.98 145,451.09 290,902.18 436,353.26 581,804.35 727,255.44	90,000 105,000 120,000 135,000 150,000 300,000 450,000 600,000 750,000 900,000 1,050,000 872,706.53 1,018,157.62 1,163,608.70 1,309,059.79 1,454,510.88 2,909,021.76 4,363,532.64 5,818,043.52 7,272,554.40 8,727,065.28 10,181,576.16 樣	1,200,000 1,350,000 1,500,000 3,000,000 4,500,000 6,000,000 7,500,000 9,000,000 9,106,500(1) 11,636,087.04 13,090,597.92 14,545,108.80 29,090,217.60 43,635,326.40 58,180,435.20 72,725,544.00 87,270,652.80 88,303,355.52 (1)Maximum number of Hong Kong Offer Shares you may apply for.
2. You, as the applicant(s), must complete the form in English (in BLOCK letters) as indicated below and sign on the second page of the Application Form. Only written signatures will be accepted (and not by way of personal chop). If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): ‧the designated CCASS Participant must endorse the form with its company chop (bearing its company name) and insert its participant I.D. in the appropriate box. If you are applying as an individual CCASS Investor Participant: ‧the form must contain your NAME and Hong Kong I.D. Card number; ‧your participant I.D. must be inserted in the appropriate box. If you are applying as a joint individual CCASS Investor Participant: ‧the form must contain all joint investor participants’ NAMES and the Hong Kong I.D. Card number of all joint investor participants; ‧your participant I.D. must be inserted in the appropriate box. If you are applying as a corporate CCASS Investor Participant: ‧the form must contain your company NAME and Hong Kong Business Registration number; Sampl

‧ your participant I.D. and your company chop (bearing your company name) must be inserted in the appropriate box.

Incorrect or omission of details of the CCASS Participant including participant I.D. and/or company chop bearing its company name or other similar matters may render your application invalid.

Staple your cheque or banker’s cashier order to the form. Each application for the Hong Kong Offer Shares must be accompanied by either one separate cheque or one separate banker’s cashier order. Your application will be rejected if your cheque or banker’s cashier order does not meet all the following requirements:
The cheque must: Banker’s cashier order must: • be in Hong Kong dollars; • not be post-dated; • be made payable to “ CMB Wing Lung (Nominees) Limited–SinoMab Public Offer ”; • be crossed “Account Payee Only”; • be drawn on your Hong Kong dollar bank account • be issued by a licensed bank in Hong Kong, and in Hong Kong; and have your name certified on the back by a person
• show your account name, which must either be authorised by the bank. The name on the banker’s pre-printed on the cheque, or be endorsed on the cashier order must correspond with your name. If back by a person authorised by the bank. This it is a joint application, the name on the back of account name must correspond with your name. If the banker’s cashier order must be the same as the it is a joint application, the account name must be first-named applicant’s name. the same as the first-named applicant’s name.
1. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker’s cashier order attached) to one of the collection boxes at any of the following branches of: CMB Wing Lung Bank Limited Branch Name Address
Hong Kong Island Head Office 45 Des Voeux Road Central Aberdeen Branch 201 Aberdeen Main Road
Kowloon Tsim Sha Tsui Branch 4 Carnavon Road Mongkok Branch B/F, CMB Wing Lung Bank Centre, 636 Nathan Road
New Territories Tsuen Wan Branch 251 Sha Tsui Road
1. Your Application Form can be lodged at these times: —
Thursday, October 31, 2019 9:00 a.m. to 5:00 p.m. —
Friday, November 1, 2019 9:00 a.m. to 5:00 p.m. —
Saturday, November 2, 2019 9:00 a.m. to 1:00 p.m. —
Monday, November 4, 2019 9:00 a.m. to 5:00 p.m. Tuesday, November 5, 2019 — 9:00 a.m. to 12:00 noon
1. The latest time for lodging your application is 12:00 noon on Tuesday, November 5, 2019. The application lists will be opened between 11:45 a.m. to 12:00 noon on that day, subject only to the weather conditions, as described in the section headed “How to Apply for Hong Kong Offer Shares – 10. Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

The applications for the Hong Kong Offer Shares will commence at 9:00 a.m. on Thursday, October 31, 2019 through 12:00 noon Tuesday, November 5, 2019. The application monies (including the brokerage fees, SFC transaction levies and Stock Exchange trading fees) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Monday, November 11, 2019. Investors should be aware that the dealings in the Shares on the Stock Exchange are expected to commence on Tuesday, November 12, 2019.

如閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

申請手續

使用下表計算閣下應付的款項。閣下申請認購的股數須至少為 300 股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。

1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為300股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。	1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為300股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。	1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為300股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。	1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為300股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。
中國抗體製藥有限公司（股份代號3681）（每股香港發售股份9.60港元）可供申請認購股份數目及應繳款項
申請認購的申請時香港發售應繳款項股份數目（港元）	申請認購的申請時香港發售應繳款項股份數目（港元）	申請認購的申請時香港發售應繳款項股份數目（港元）	申請認購的申請時香港發售應繳款項股份數目（港元）
300 600 900 1,200 1,500 1,800 2,100 2,400 2,700 3,000 4,500 2,909.02 5,818.05 8,727.06 11,636.09 14,545.11 17,454.13 20,363.15 23,272.17 26,181.20 29,090.22 43,635.33	6,000 7,500 9,000 10,500 12,000 13,500 15,000 30,000 45,000 60,000 75,000 58,180.44 72,725.54 87,270.65 101,815.76 116,360.87 130,905.98 145,451.09 290,902.18 436,353.26 581,804.35 727,255.44	90,000 105,000 120,000 135,000 150,000 300,000 450,000 600,000 750,000 900,000 1,050,000 872,706.53 1,018,157.62 1,163,608.70 1,309,059.79 1,454,510.88 2,909,021.76 4,363,532.64 5,818,043.52 7,272,554.40 8,727,065.28 10,181,576.16 樣	1,200,000 1,350,000 1,500,000 3,000,000 4,500,000 6,000,000 7,500,000 9,000,000 9,106,500(1) 11,636,087.04 13,090,597.92 14,545,108.80 29,090,217.60 43,635,326.40 58,180,435.20 72,725,544.00 87,270,652.80 88,303,355.52 (1) 閣下可申請認購的香港發售股份最高數目。
2. 閣下作為申請人，必須按照下列指示以英文正楷填妥表格，並於申請表格次頁簽署，只接納親筆簽名（不得以個人印章代替）。如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請： ‧ 該指定中央結算系統參與者必須於表格蓋上公司印鑑（附有公司名稱），並在適當方格內填寫參與者編號。如閣下以個人中央結算系統投資者戶口持有人名義提出申請： ‧ 表格須載有閣下的姓名和香港身份證號碼； ‧ 須在適當方格內填寫閣下的參與者編號。如閣下以聯名個人中央結算系統投資者戶口持有人名義提出申請： ‧ 表格須載有所有聯名投資者戶口持有人的姓名和香港身份證號碼； ‧ 須在適當方格內填寫閣下的參與者編號。如閣下以公司中央結算系統投資者戶口持有人名義提出申請： ‧ 表格須載有閣下的公司名稱和香港商業登記號碼； ‧ 須在適當方格內填寫閣下的參與者編號並蓋上公司印鑑（附有公司名稱）。 Sampl

中央結算系統參與者的資料（包括參與者編號及╱或顯示公司名稱之公司印鑑）或其他類似事項如有不確或遺漏，均可能導致申請無效。

閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出支票或一張獨立開出銀行本票。支票或銀行本票必須符合以下所有規定，否則有關的認購申請不獲接納：

支票必須：銀行本票必須： ‧ 為港元； ‧ 不得為期票； ‧ 註明抬頭人為「 招商永隆受託代管有限公司－中國抗體製藥公開發售 」； ‧ 劃線註明「只准入抬頭人賬戶」； ‧ ‧ 從閣下在香港的港元銀行賬戶中開出；及須由香港持牌銀行開出，並由有關銀行授權 ‧ 顯示閣下的賬戶名稱，而該賬戶名稱必須的人士在銀行本票背面簽署核證閣下姓名已預印在支票上，或由有關銀行授權的人士 ╱名稱。銀行本票所示姓名╱名稱須與閣在支票背書。賬戶名稱必須與閣下姓名╱ 下姓名╱名稱相同。如屬聯名申請，銀行本名稱相同。如屬聯名申請，賬戶名稱必須與票背面所示姓名╱名稱必須與排名首位申請排名首位申請人的姓名╱名稱相同。人的姓名╱名稱相同。 4. 請撕下申請表格，對摺一次，然後將填妥的申請表格（連同支票或銀行本票）投入下列任何一家分行的收集箱： 招商永隆銀行有限公司分行名稱地址港島區 總行德輔道中 45 號香港仔分行香港仔大道 201 號 九龍區 尖沙咀分行加拿分道 4 號旺角分行彌敦道 636 號招商永隆銀行中心地庫 新界區 荃灣分行沙咀道 251 號 5. 閣下可於下列時間遞交申請表格：二零一九年十月三十一日（星期四）－上午九時正至下午五時正二零一九年十一月一日（星期五）－上午九時正至下午五時正二零一九年十一月二日（星期六）－上午九時正至下午一時正二零一九年十一月四日（星期一）－上午九時正至下午五時正二零一九年十一月五日（星期二）－上午九時正至中午十二時正

請撕下申請表格，對摺一次，然後將填妥的申請表格（連同支票或銀行本票）投入下列任何一家分行的收集箱：
截止遞交申請的時間為二零一九年十一月五日（星期二）中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間登記認購申請，惟僅受招股章程「如何申請香港發售股份－ 10. 惡劣天氣對開始辦理申請登記的影響」一節所述的天氣情況所限。

香港發售股份申請將會自二零一九年十月三十一日（星期四）上午九時正起直至二零一九年十一月五日（星期二）中午十二時正止。申請款項（包括經紀佣金、證監會交易徵費及聯交所交易費）將由收款銀行於截止辦理申請登記後代表本公司持有，且退款金額（如有）將於二零一九年十一月十一日（星期一）或之前不計利息退還予申請人。投資者務請注意，預期股份將於二零一九年十一月十二日（星期二）於聯交所開始買賣。

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant SinoMab BioScience Limited 中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability) GLOBAL OFFERING
Conditions of your application ‧ agree that none of the Company, the Joint Sponsors, the Joint A. Who can apply Global Coordinators, the Joint Bookrunners, the Joint Lead 1. You and any person(s) for whose benefit you are applying must Managers, the Underwriters, their respective directors, officers, employees, partners, agents, advisors nor any other parties
be 18 years of age or older, must have a Hong Kong address and must be outside the United States and not a United States involved in the Global Offering is or will be liable for any information and representations not in the Prospectus (and any
Person (as defined in Regulation S under the U.S. Securities supplement to it);
1. If you are a firm, the application must be in the individual Act) and not be a legal or natural person of the PRC. ‧ undertake and confirm that you or the person(s) for whose members’ names. benefit you have made the application have not applied for or
1. The number of joint applicants may not exceed 4. taken up, or indicated an interest for, and will not apply for 4. If you are a body corporate, the application must be signed or take up, or indicate an interest for, any Offer Shares under the International Offering nor participated in the International
by a duly authorised officer, who must state his representative
1. Unless permitted by the Listing Rules or any relevant waivers capacity, and stamped with your corporation’s chop. ‧ agree Offering; to disclose to the Company, the Hong Kong Share Registrar, receiving bank, the Joint Sponsors, the Joint Global
that have been granted by the Stock Exchange, you cannot Coordinators, the Joint Bookrunners, the Joint Lead Managers,
apply for any Hong Kong Offer Shares if you are: ‧ the Underwriters and/or their respective advisors and agents an existing beneficial owner of shares in the Company any personal data which they may require about you and the
and/or any of its subsidiaries;
‧ person(s) for whose benefit you have made the application; a Director or chief executive officer of the Company and/ ‧ if the laws of any place outside Hong Kong apply to your or any of its subsidiaries;
‧ application, agree and warrant that you have complied with a close associate (as defined under the Listing Rules) of all such laws and none of the Company, the Joint Sponsors, the
any of the above;
‧ Joint Global Coordinators, the Joint Bookrunners, the Joint Lead a core connected person (as defined under the Listing Managers, the Underwriters nor any of their respective officers,
Rules) of the Company or will become a core connected advisors and agents will breach any law outside Hong Kong
person (as defined under the Listing Rules) of the as a result of the acceptance of your offer to purchase, or any
Company immediately upon completion of the Global action arising from your rights and obligations under the terms
Offering; or
‧ and conditions contained in the Prospectus and this Application have been allocated or have applied for or indicated Form;
an interest in any Offer Shares under the International ‧ agree that once your application has been accepted, you may Offering. not rescind it because of an innocent misrepresentation;
B. If you are a nominee ‧ agree that your application will be governed by the laws of
You, as a nominee, may make more than one application for the Hong Kong;
Hong Kong Offer Shares by: (i) giving electronic instructions to ‧ represent , warrant and undertake that (i) you understand HKSCC via Central Clearing and Settlement System (“ CCASS ”) (if that the Hong Kong Offer Shares have not been and will not
you are a CCASS Participant); or (ii) using a WHITE or YELLOW be registered under the U.S. Securities Act; and (ii) you and
Application Form, and lodge more than one application in your own any person for whose benefit you are applying for the Hong
name on behalf of different beneficial owners. Kong Offer Shares are outside the United States (as defined in
C. Effect of completing and submitting this Application Form Regulation S) or are a person described in paragraph (h)(3) of By completing and submitting this Application Form, you (and if you Rule 902 of Regulation S; are joint applicants, each of you jointly and severally) for yourself or ‧ warrant that the information you have provided is true and as an agent or a nominee on behalf of each person for whom you act: accurate; ‧ undertake to execute all relevant documents and instruct and ‧ agree to accept the Hong Kong Offer Shares applied for, or any authorise the Company and/or the Joint Global Coordinators (or lesser number allocated to you under the application; their agents or nominees), as agents of the Company, to execute ‧ authorise the Company to place the name of the HKSCC any documents for you and to do on your behalf all things Nominees on the Company’s register of members as the necessary to register any Hong Kong Offer Shares allocated holder(s) of any Hong Kong Offer Shares allocated to you, and to you in the name of HKSCC Nominees as required by the the Company and/or its agents to deposit any share certificate(s) Articles of Association; into CCASS and/or to send any refund cheque(s) to you or the
‧ agree to comply with the Companies Ordinance (Chapter 622 first-named applicant for joint application by ordinary post at of the Laws of Hong Kong), the Companies (Winding Up and your own risk to the address stated on the application, unless Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws you have fulfilled the criteria set out in the section headed “How of Hong Kong) and the Articles of Association; to Apply for Hong Kong Offer Shares – 14. Dispatch/Collection
‧ confirm that you have read the terms and conditions and of Share Certificates and Refund Monies – Personal Collection” application procedures set out in the Prospectus and in this in the Prospectus to collect refund cheque(s) in person;
‧ confirm that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;
‧ agree that the shares to be allotted shall be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your investor participant stock account or the stock account of your designated CCASS Participant;
‧ confirm that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;
‧ agree that each of HKSCC and HKSCC Nominees reserves the right (1) not to accept any or part of such allotted shares issued in the name of HKSCC Nominees or not to accept such allotted shares for deposit into CCASS; (2) to cause such allotted shares
‧ confirm that you are aware of the restrictions on the Global Offering in the Prospectus;

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares under the Hong Kong Public Offering following such reallocation shall be not more than 36,426,000 Offer Shares, representing double of the initial allocation to the Hong Kong Public Offering, and the final Offer Price shall be fixed at the low-end of the indicative offer price range (i.e. HK$7.60 per Offer Share).

to be withdrawn from CCASS and issued in your name at your own risk and costs; and (3) to cause such allotted shares to be issued in your name (or, if you are a joint applicant, to the firstnamed applicant) and in such a case, to post the certificates for such allotted shares at your own risk to the address on your application form by ordinary post or to make available the same for your collection;

‧ agree that each of HKSCC and HKSCC Nominees may adjust If your application for Hong Kong Offer Shares is successful (in whole or in par t ) the number of allotted shares issued in the name of HKSCC If your application is wholly or partially successful, your share ‧ Nominees; agree that neither HKSCC nor HKSCC Nominees shall have certificate(s) (subject to their becoming valid certificates of title provided that the Hong Kong Public Offering has become any liability for the information and representations not so unconditional and not having been terminated at 8:00 a.m. on ‧ contained in the Prospectus and this Application Form; agree that neither HKSCC nor HKSCC Nominees shall be Tuesday, November 12, 2019) will be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your ‧ liable to you in any way; declare and represent that this is the only application made and CCASS Investor Participant stock account or the stock account of your designated CCASS Participant as instructed by you in your the only application intended by you to be made to benefit you Application Form on Monday, November 11, 2019 or, in the event of ‧ or the person for whose benefit you are applying; understand that the Company and the Joint Global a contingency, on any other date as shall be determined by HKSCC or HKSCC Nominees. Coordinators will rely on your declarations and representations ‧ If you are applying through a designated CCASS Participant in deciding whether or not to make any allotment of any of the (other than a CCASS Investor Participant): For Hong Kong Hong Kong Offer Shares to you and that you may be prosecuted Offer Shares credited to the stock account of your designated ‧ for making a false declaration;(if the application is made for your own benefit) warrant that CCASS Participant (other than a CCASS Investor Participant), you can check the number of Hong Kong Offer Shares allotted no other application has been or will be made for your benefit to you with that CCASS Participant. on a WHITE or YELLOW Application Form or by giving ‧ If you are applying as a CCASS Investor Participant: The electronic application instructions to HKSCC or to the White Company expects to publish the results of CCASS Investor Form eIPO Service Provider by you or by any one as your Participants’ applications together with the results of the ‧ (if you are making the application as an agent for the benefit of agent or by any other person; and Hong Kong Public Offering on the website of the Stock Exchange at www.hkexnews.hk and the Company’s website another person) warrant that (i) no other application has been or at www.sinomab.com on Monday, November 11, 2019. You will be made by you as agent for or for the benefit of that person should check the announcement published by the Company or by that person or by any other person as agent for that person and report any discrepancies to HKSCC before 5:00 p.m. on on a WHITE or YELLOW Application Form or by giving Monday, November 11, 2019 or such other date as shall be electronic application instructions to HKSCC; and (ii) you have determined by HKSCC or HKSCC Nominees. Immediately due authority to sign the Application Form or give electronic after the credit of the Hong Kong Offer Shares to your stock application instructions on behalf of that other person as their account you can check your new account balance via the agent. CCASS Phone System and CCASS Internet System (under D. Power of attorney the procedures contained in HKSCC’s “An Operating Guide If your application is made through an authorised attorney, the for Investor Participants” in effect from time to time). HKSCC Company and the Joint Global Coordinators may accept or reject your will also make available to you an activity statement showing application at their discretion, and on any conditions they think fit, the number of Hong Kong Offer Shares credited to your stock including evidence of the attorney’s authority. account. Determination of Offer Price and Allocation of Hong Kong Offer No receipt will be issued for application money paid. The Company Shares will not issue temporary documents of title. The Offer Price is expected to be fixed on or around Tuesday, Refund of your money November 5, 2019. Applicants are required to pay the maximum If you do not receive any Hong Kong Offer Shares or if your Offer Price of HK$9.60 for each Hong Kong Offer Share together application is accepted only in part, the Company will refund to you with 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock your application monies (including the related 1% brokerage, 0.0027% Exchange trading fee. If the Offer Price is not agreed among the SFC transaction levy and 0.005% Stock Exchange trading fee) without Company and the Joint Global Coordinators (for themselves and on interest. If the Offer Price is less than the maximum Offer Price, the behalf of the Underwriters) on or before Wednesday, November 6, Company will refund to you the surplus application monies (including 2019, the Global Offering will not proceed. the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% Applications for Hong Kong Offer Shares will not be processed and Stock Exchange trading fee) without interest. no allotment of any Hong Kong Offer Shares will be made until the The refund procedures are stated in the section headed “How to Apply application lists close. for Hong Kong Offer Shares – 14. Dispatch/Collection of Share The Company expects to announce the final Offer Price, the indication Certificates and Refund Monies” in the Prospectus. of the level of interest in the International Offering, the level of Effect of the Information You Give Us applications under the Hong Kong Public Offering and the basis of Computershare Hong Kong Investor Services Limited and its allocation of the Hong Kong Offer Shares on Monday, November 11, 2019 on the website of the Stock Exchange at www.hkexnews.hk and related bodies’ corporate, directors, officers, employees and agents the Company’s website at www.sinomab.com . Results of allocations (“ Representatives ”) expressly disclaim and exclude to the maximum

Computershare Hong Kong Investor Services Limited and its related bodies’ corporate, directors, officers, employees and agents (“ Representatives ”) expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.

and the Hong Kong Identity Card/passport/Hong Kong business registration numbers of successful applicants (where applicable) will be available on the above websites.

The allocation of Offer Shares between the Hong Kong Public Offering and the International Offering is subject to adjustment as detailed in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to

如閣下欲以香港中央結算（代理人）有限公司（「香港結算代理人」）的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統（「中央結算系統」），以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格 SinoMab BioScience Limited 中國抗體製藥有限公司（於香港註冊成立的有限公司） 全球發售
申請條件 球發售的任何其他各方現時及日後均毋須對並非載於招股章程（及其任何補充文件）的任何資料及陳述負
甲、可提出申請的人士 責； 1. 閣下及閣下為其利益提出申請的人士必須年滿 18 歲 ‧ 承諾及確認閣下或閣下為其利益提出申請的人士並有香港地址，身處美國境外且並非美籍人士（定義並無申請或接納或表示有意認購（亦不會申請或接納
見美國證券法 S 規例）及並非中國法人或自然人。或表示有意認購）國際發售的任何發售股份，也沒有
1. 如閣下為商號，申請須以個別成員名義提出。參與國際發售；
1. 聯名申請人不得超過四名。 ‧ 同意向本公司、香港證券登記處、收款銀行、聯席保 4. 如閣下為法人團體，申請須經獲正式授權人員簽薦人、聯席全球協調人、聯席賬簿管理人、聯席牽頭
署，並註明其所屬代表身份及蓋上公司印鑑。經辦人、包銷商及╱或彼等各自的顧問及代理披露其
1. 除上市規則或聯交所已授予的任何相關豁免外，下列所要求有關閣下及閣下為其利益提出申請的人士
人士概不得申請認購任何香港發售股份：的個人資料；
‧ 本公司及╱或其任何附屬公司股份的現有實益擁 ‧ 若香港境外任何地方的法例適用於閣下的申請，則有人；同意及保證閣下已遵守所有有關法例，且本公司、
‧ 本公司及╱或其任何附屬公司的董事或行政總聯席保薦人、聯席全球協調人、聯席賬簿管理人、聯裁；席牽頭經辦人、包銷商及彼等各自的高級職員、顧問
‧ 上述任何人士的緊密聯繫人（定義見上市規則）；及代理概不會因接納閣下的購買要約，或閣下在
‧ 本公司核心關連人士（定義見上市規則）或緊隨全招股章程及本申請表格所載的條款及條件項下的權利
球發售完成後將成為本公司核心關連人士（定義及責任所引致的任何行動，而違反香港境外的任何法
見上市規則）的人士；或例；
‧ 已獲分配或已申請或表示有意申請國際發售的任 ‧ 同意閣下的申請一經接納，即不得因無意的失實陳何發售股份。述而撤銷；
‧ 同意閣下的申請受香港法例規管；
乙、如閣下為代名人 ‧ 表示、保證及承諾 (i) 閣下明白香港發售股份並無及
閣下作為代名人可提交超過一份香港發售股份申請，方法將不會根據美國證券法登記；及 (ii) 閣下及閣下
是：(i) 透過中央結算及交收系統（「 中央結算系統 」）向香為其利益提出申請香港發售股份的任何人士身處美國
港結算發出電子認購指示（如閣下為中央結算系統參與境外（定義見 S 規例），或屬 S 規例第 902 條第 (h)(3) 段
者）；或 (ii) 使用白色或黃色申請表格以自身名義代表不同所述的人士；
的實益擁有人提交超過一份申請。 ‧ 保證閣下提供的資料真實及準確；
丙、填交本申請表格的效用 ‧ 同意接納所申請數目或根據申請分配予閣下但數目閣下填妥並遞交本申請表格，即表示閣下（如屬聯名申請較少的香港發售股份；人，即各人共同及個別）代表閣下本身，或作為閣下代 ‧ 授權本公司將香港結算代理人的名稱列入本公司股東其行事的每位人士的代理或代名人：名冊，作為閣下獲分配的任何香港發售股份的持有 ‧ 承諾簽立所有相關文件，並指示及授權本公司及╱或人，並授權本公司及╱或其代理將任何股票存入中聯席全球協調人（或彼等的代理或代名人）（作為本公央結算系統及╱或以普通郵遞方式按申請所示地址司代理）為閣下簽立任何文件及代表閣下辦理一向閣下或聯名申請的首名申請人發送任何退款支切必要事宜，以按照章程細則的規定將閣下獲分配票，郵誤風險由閣下承擔，除非閣下已符合招股的任何香港發售股份以香港結算代理人的名義登記；章程「如何申請香港發售股份－14. 發送╱領取股票及
‧ 退回股款－親身領取」一節的條件親身領取退款支票；
‧ 同意遵守香港法例第 622 章公司條例、香港法例第 32 章公司（清盤及雜項條文）條例及章程細則；
‧ 同意獲配發的股份是以香港結算代理人的名義發行，並直接存入中央結算系統，以便記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下的指定中央結算系統參與者股份戶口；
‧ 確認閣下已細閱招股章程及本申請表格所載的條款及條件以及申請程序，並同意受其約束；
‧ 確認閣下已接獲及細閱招股章程，提出申請時也僅依據招股章程載列的資料及陳述，而除招股章程任何補充文件外，不會依賴任何其他資料或陳述；
‧ 同意香港結算及香港結算代理人各自保留權利 (1) 不接納以香港結算代理人名義發行的該等獲配發的任何或部分股份，或不接納該等獲配發的股份存入中央結算系統；(2) 促使該等獲配發的股份從中央結算系統提取，並轉入閣下名下，有關風險及費用概由閣下自行承擔；及 (3) 促使該等獲配發的股份以閣下
‧ 確認閣下知悉招股章程內有關全球發售的限制；
‧ 同意本公司、聯席保薦人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、包銷商及彼等各自的董事、高級職員、僱員、合夥人、代理、顧問及參與全

名義發行（或如屬聯名申請人，則以排名首位申請人的名義發行），而在此情況下，會以普通郵遞方式將該等獲配發股份的股票寄往閣下在申請表格上所示地址（郵誤風險概由閣下自行承擔）或提供該等股票予閣下領取；

如閣下成功申請認購香港發售股份（全部或部分）

的名義發行），而在此情況下，會以普通郵遞方式將如閣下的申請全部或部分獲接納，閣下的股票（前提是該等獲配發股份的股票寄往閣下在申請表格上所示到二零一九年十一月十二日（星期二）上午八時正香港公開地址（郵誤風險概由閣下自行承擔）或提供該等股票發售成為無條件而並無終止，股票成為有效的所有權證明）予閣下領取；將以香港結算代理人名義發出，並按閣下在申請表格的 ‧ 同意香港結算及香港結算代理人均可調整獲配發以香指示於二零一九年十一月十一日（星期一）或在特別情況下港結算代理人名義發行的股份數目；由香港結算或香港結算代理人指定的任何其他日期直接存 ‧ 同意香港結算及香港結算代理人對招股章程及本申請入中央結算系統，記入閣下的中央結算系統投資者戶口表格未有載列的資料及陳述概不負責；持有人股份戶口或閣下指定的中央結算系統參與者股份 ‧ 同意香港結算及香港結算代理人概不以任何方式戶口。對閣下負責； ‧ 如閣下透過中央結算系統投資者戶口持有人以外的 ‧ 聲明及陳述此乃閣下為本身或為其利益提出申請的指定中央結算系統參與者提出申請：香港發售股份將人士所提出及擬提出的唯一申請；存入閣下指定的中央結算系統參與者（非中央結算 ‧ 明白本公司及聯席全球協調人將依據閣下的聲明系統投資者戶口持有人）股份戶口，閣下可向該中央及陳述而決定是否向閣下分配任何香港發售股結算系統參與者查詢閣下獲配發的香港發售股份數份，閣下如作出虛假聲明，可能會被檢控；目。 ‧ （如本申請是為閣下本身利益提出）保證閣下或作 ‧ 如閣下以中央結算系統投資者戶口持有人身份提出為閣下代理的任何人士或任何其他人士不曾亦不會申請：本公司預期於二零一九年十一月十一日（星期為閣下利益而以白色或黃色申請表格或向香港結算一）在聯交所網站 ( www.hkexnews.hk ) 及本公司網站或向 白表 eIPO 服務供應商發出 電子認購指示 而提出 ( www.sinomab.com ) 刊登中央結算系統投資者戶口持其他申請；及有人的申請結果及香港公開發售的結果。閣下應查 ‧ （如閣下作為代理為另一人士的利益提出申請）保證閱本公司刊發的公告，如有任何資料不符，請於二零 (i) 閣下（作為代理或為該人士利益）或該人士或任何一九年十一月十一日（星期一）下午五時正或香港結算其他作為該人士代理的人士不曾亦不會以白色或黃色或香港結算代理人釐定的任何其他日期前知會香港結申請表格或向香港結算發出 電子認購指示 而提出其他算。在香港發售股份存入閣下的股份戶口後，閣申請；及 (ii) 閣下獲正式授權作為該人士的代理代下即可透過「結算通」電話系統及中央結算系統互聯網。為簽署本申請表格或發出 電子認購指示 系統（根據香港結算不時生效的「投資者戶口操作簡介」所載程序）查詢閣下的新戶口結餘。香港結算亦 丁、授權書 將向閣下提供一份活動結單，列出存入閣下股份如閣下透過授權人士提出申請，本公司及聯席全球協調戶口的香港發售股份數目。人可按其認為合適的條件（包括出示獲授權證明）酌情接納本公司不會就申請時繳付的款項發出收據，亦不會發出臨或拒絕閣下的申請。時所有權文件。 釐定發售價及香港發售股份的分配退回款項 預期發售價於二零一九年十一月五日（星期二）或前後釐若閣下未獲分配任何香港發售股份或申請僅部分獲接定。申請人須繳付每股香港發售股份 9.60 港元的最高發納，本公司將不計利息退回閣下的申請股款（包括相關的售價，另加 1% 經紀佣金、0.0027% 證監會交易徵費及 1% 經紀佣金、0.0027% 證監會交易徵費及 0.005% 聯交所 0.005% 聯交所交易費。倘若本公司與聯席全球協調人（為交易費）。如發售價低於最高發售價，本公司將不計利息退其自身及代表包銷商）並無於二零一九年十一月六日（星期回多收申請股款（包括相關的 1% 經紀佣金、0.0027% 證監三）或之前協定發售價，全球發售將不會進行。會交易徵費及 0.005% 聯交所交易費）。截止登記認購申請前，概不處理香港發售股份的申請或配有關退款程序載於招股章程「如何申請香港發售股份－發任何香港發售股份。 14. 發送╱領取股票及退回款項」一節。本公司預期於二零一九年十一月十一日（星期一）在聯交所網站 ( www.hkexnews.hk ) 及本公司網站 ( www.sinomab.com ) 公 您提供給我們的資訊的有關影響 佈最終發售價、國際發售踴躍程度、香港公開發售認購申香港中央證券登記有限公司和其有關連的法人團體、董請水平及香港發售股份分配基準。分配結果以及獲接納申事、高級人員、僱員及代理人（「代表」）在法律所容許的最請人的香港身份證╱護照╱香港商業登記號碼（如適用）亦大限度內明確卸棄及免除在任何方面與申請人或代表申請同於上述網站公佈。人在此文件提供的或與此文件或在此文件下提供的任何服

香港中央證券登記有限公司和其有關連的法人團體、董事、高級人員、僱員及代理人（「代表」）在法律所容許的最大限度內明確卸棄及免除在任何方面與申請人或代表申請人在此文件提供的或與此文件或在此文件下提供的任何服務相關的任何資料，或任何申請人或代表申請人提供與此文件或在此文件下提供的任何服務相關的任何其它書面或口頭通訊，有關或相關由申請人或任何其他人士或實體所遭受或招致不論如何造成的任何損失或損害的任何法律責任。此包括，但不限於，該等資料中不論如何造成的任何錯誤或遺漏，或代表或任何其他人士或實體對該等資料或任何該等資料的文件記錄、影像、記錄或複製品作出的任何依據，或其準確性、完整性、合時性或可靠性。

發售股份在香港公開發售與國際發售之間的分配可如招股章程「全球發售的架構－香港公開發售－重新分配」一節所述調整。特別是，聯席全球協調人可將發售股份由國際發售重新分配至香港公開發售，以滿足香港公開發售項下的有效申請。根據聯交所發表的指引信 HKEX-GL91-18，倘有關重新分配並非根據上市規則第 18 項應用指引完成，有關重新分配後，香港公開發售的發售股份總數最多將不超過 36,426,000 股發售股份，相當於初步分配至香港公開發售股份數目的兩倍，而最終發售價將為指示性發售價範圍的下限（即每股發售股份 7.60 港元）。

Please use this form if you want the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees Limited (“HKSCC Nominees”) and deposited directly into the Central Clearing and Settlement System (“CCASS”) for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant

Personal Data ‧ any other incidental or associated purposes relating Personal Information Collection Statement to the above and/or to enable the Company and This Personal Information Collection Statement informs the Hong Kong Share Registrar to discharge their obligations to securities’ holders and/or regulators the applicant for, and holder of, Hong Kong Offer Shares, and/or any other purposes to which the securities’ of the policies and practices of the Company and its Hong holders may from time to time agree. Kong Share Registrar in relation to personal data and the 3. Transfer of personal data Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “ Ordinance ”). Personal data held by the Company and its Hong Kong Share Registrar relating to the securities holders will be 1. Reasons for the collection of your personal data kept confidential but the Company and its Hong Kong It is necessary for applicants and registered holders of Share Registrar may, to the extent necessary for achieving securities to supply correct personal data to the Company any of the above purposes, disclose, obtain or transfer or its agents and the Hong Kong Share Registrar when (whether within or outside Hong Kong) the personal data applying for securities or transferring securities into or out to, from or with any of the following: of their names or in procuring the services of the Hong ‧ the Company’s appointed agents such as financial Kong Share Registrar. advisers, receiving bankers and overseas principal share registrar; Failure to supply the requested data may result in your ‧ where applicants for securities request a deposit into application for securities being rejected, or in delay or CCASS, HKSCC or HKSCC Nominees, who will the inability of the Company or its Hong Kong Share use the personal data for the purposes of operating Registrar to effect transfers or otherwise render their CCASS; services. It may also prevent or delay registration or ‧ any agents, contractors or third-party service providers transfers of the Hong Kong Offer Shares which you have who offer administrative, telecommunications, successfully applied for and/or the dispatch of share computer, payment or other services to the Company certificate(s) and/or refund cheque(s) to which you are or the Hong Kong Share Registrar in connection entitled. with their respective business operation; It is important that securities holders inform the Company ‧ the Stock Exchange, the SFC and any other statutory and the Hong Kong Share Registrar immediately of any regulatory or governmental bodies or otherwise as inaccuracies in the personal data supplied. required by laws, rules or regulations; and 2. Purposes ‧ any persons or institutions with which the securities’ holders have or propose to have dealings, such as The personal data of the securities holders may be used, their bankers, solicitors, accountants or stockbrokers held, processed, and/or stored (by whatever means) for etc. the following purposes: ‧ 4. Retention of personal data processing your application and refund cheque, The Company and its Hong Kong Share Registrar will where applicable, verification of compliance with keep the personal data of the applicants and holders of the terms and application procedures set out in securities for as long as necessary to fulfil the purposes this Application Form and the Prospectus and for which the personal data were collected. Personal data announcing results of allocation of the Hong Kong which is no longer required will be destroyed or dealt Offer Shares; with in accordance with the Ordinance. ‧ compliance with applicable laws and regulations in 5. Access to and correction of personal data Hong Kong and elsewhere; ‧ Securities holders have the right to ascertain whether registering new issues or transfers into or out of the Company or the Hong Kong Share Registrar hold the names of securities’ holders including, where their personal data, to obtain a copy of that data, and to applicable, HKSCC Nominees; ‧ maintaining or updating the register of securities’ correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a holders of the Company; reasonable fee for the processing of such requests.

‧ verifying securities holders’ identities;

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the section headed “Corporate Information” in the Prospectus or as notified from time to time, for the attention of the company secretaries, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

‧ establishing benefit entitlements of securities’ holders of the Company, such as dividends, rights issues, bonus issues, etc.;
‧ distributing communications from the Company and its subsidiaries;
‧ compiling statistical information and securities’ holders profiles;

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

‧ disclosing relevant information to facilitate claims on entitlements; and

‧ 個人資料 與上述有關的任何其他附帶或相關目的及╱ 或使本公司及香港證券登記處能履行對證券 個人資料收集聲明 持有人及╱或監管機構承擔的責任及╱或證券持有人不時同意的任何其他目的。此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及其香港證券登記處 3. 轉交個人資料 有關個人資料和香港法例第 486 章《個人資料（私本公司及其香港證券登記處所持有關證券持有人隱）條例》（「（「條例」）方面的政策和措施。的個人資料將會保密，但本公司及其香港證券登記處可以在為達到上述任何目的之必要情況下， 1. 收集閣下個人資料的原因 向下列任何人士披露，獲取或轉交（無論在香港證券申請人及登記持有人以本身名義申請證券或境內或境外）有關個人資料： ‧ 轉讓或受讓證券時或尋求香港證券登記處的服務本公司委任的代理人，例如財務顧問、收款銀行和海外主要股份過戶登記分處；時，必須向本公司或其代理人及香港證券登記處 ‧ 如證券申請人要求將證券存於中央結算系提供準確個人資料。統、香港結算或香港結算代理人；彼等將會就中央結算系統的運作使用有關個人資料；未能提供所要求的資料可能導致閣下申請證券 ‧ 向本公司或香港證券登記處提供與其各自業被拒或延遲，或本公司或其香港證券登記處無法務營運有關的行政、電訊、電腦、付款或其落實轉讓或提供服務。此舉也可能妨礙或延遲登他服務的任何代理人、承包商或第三方服務供應商；記或轉讓閣下成功申請的香港發售股份及╱或 ‧ 聯交所、證監會及任何其他法定監管機關或寄發閣下應得的股票及╱或退款支票。政府部門或其他法例、規則或法規另行規定者；及證券持有人所提供的個人資料如有任何錯誤，須 ‧ 證券持有人與其進行或擬進行交易的任何人立即通知本公司及香港證券登記處。士或機構，例如彼等的銀行、律師、會計師或股票經紀等。 2. 目的 證券持有人的個人資料可被採用及以任何方式持 4. 個人資料的保留 有、處理及╱或保存，以作下列用途：本公司及其香港證券登記處將按收集個人資料所 ‧ 處理閣下的申請及退款支票（如適用）、核需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。實是否符合本申請表格及招股章程載列的條款和申請程序以及公佈香港發售股份的分配 5. 查閱和更正個人資料 結果；證券持有人有權確定本公司或香港證券登記處是 ‧ 遵守香港及其他地區的適用法律及法規；否持有其個人資料，並有權索取有關該資料的副 ‧ 以證券持有人（包括香港結算代理人（如適本並更正任何不準確資料。本公司和香港證券登記處有權就處理任何查閱資料的要求收取合理費用））的名義登記新發行證券或轉讓或受讓證用。券；

本公司及其香港證券登記處所持有關證券持有人隱）條例》（「（「條例」）方面的政策和措施。的個人資料將會保密，但本公司及其香港證券登記處可以在為達到上述任何目的之必要情況下， 1. 收集閣下個人資料的原因 向下列任何人士披露，獲取或轉交（無論在香港證券申請人及登記持有人以本身名義申請證券或境內或境外）有關個人資料： ‧ 轉讓或受讓證券時或尋求香港證券登記處的服務本公司委任的代理人，例如財務顧問、收款銀行和海外主要股份過戶登記分處；時，必須向本公司或其代理人及香港證券登記處 ‧ 如證券申請人要求將證券存於中央結算系提供準確個人資料。統、香港結算或香港結算代理人；彼等將會就中央結算系統的運作使用有關個人資料；未能提供所要求的資料可能導致閣下申請證券 ‧ 向本公司或香港證券登記處提供與其各自業被拒或延遲，或本公司或其香港證券登記處無法務營運有關的行政、電訊、電腦、付款或其落實轉讓或提供服務。此舉也可能妨礙或延遲登他服務的任何代理人、承包商或第三方服務供應商；記或轉讓閣下成功申請的香港發售股份及╱或 ‧ 聯交所、證監會及任何其他法定監管機關或寄發閣下應得的股票及╱或退款支票。政府部門或其他法例、規則或法規另行規定者；及證券持有人所提供的個人資料如有任何錯誤，須 ‧ 證券持有人與其進行或擬進行交易的任何人立即通知本公司及香港證券登記處。士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

‧ 存置或更新本公司證券持有人的名冊；

所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向本公司的香港證券登記處的私隱事務主任提出。

‧ 核實證券持有人的身份；
‧ 確定本公司證券持有人的受益權利，例如股息、供股和紅股等；
‧ 分發本公司及其附屬公司的通訊；

閣下簽署申請表格或向香港結算發出電子認購指示，即表示同意上述各項。

‧ 編製統計數據和證券持有人資料；
‧ 披露有關資料以便就權益索償；及

AI assistant

SinoMab BioScience Limited Share Issue/Capital Change 2019

50863_rns_2019-10-30_398eb478-bf44-4d72-b4d8-3871779b5642.pdf

Applicants’ declaration

申請人聲明

How to make your application

申請手續

如閣下成功申請認購香港發售股份（全部或部分）

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

AI assistant

SinoMab BioScience Limited — Share Issue/Capital Change 2019

50863_rns_2019-10-30_398eb478-bf44-4d72-b4d8-3871779b5642.pdf

Applicants’ declaration

申請人聲明

How to make your application

申請手續

如 閣下成功申請認購香港發售股份（全部或部分）

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

More from SinoMab BioScience Limited

SinoMab BioScience Limited Share Issue/Capital Change 2019

如閣下成功申請認購香港發售股份（全部或部分）